Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 1 Individual characteristics in TCGA datasets

From: Common polymorphic inversions at 17q21.31 and 8p23.1 associate with cancer prognosis

 Lung1 (n = 381)Lung2 (n = 399)Liver (n = 140)Colorectal (n = 470)Stomach (n = 240)Breast (n = 734)
Inv8p23.1      
 Std-Std59 (15.5%)81 (20.3%)21 (15.0%)88 (18.7%)55 (22.9%)128 (17.5%)
 Std-Inv205 (53.8%)207 (51.9%)83 (59.3%)219 (46.6%)115 (47.9%)376 (51.2%)
 Inv-Inv117 (30.7%)111 (27.8%)36 (25.7%)163 (34.7%)14 (29.2%)230 (31.3%)
Inv17q21.31      
 Std-Std225 (59.1%)244 (61.1%)83 (59.3%)294 (62.7%)158 (65.8%)453 (61.7%)
 Std-Inv140 (36.7%)128 (32.1%)49 (35.0%)162 (34.5%)68 (28.3%)250 (34.1%)
 Inv-Inv16 (4.2%)27 (6.8%)8 (5.7%)14 (2.97%)14 (5.8%)31 (4.2%)
Age (years)67 (33-88)69 (40-90)65 (17-85)69 (31-90)67 (41-90)60 (26-90)
Sex      
 Women205 (53.8%)99 (24.8%)68 (48.6%)225 (47.9%)93 (38.8%)734 (100%)
 Men176 (46.2%)300 (75.2%)72 (51.2%)245 (52.1%)147 (61.3%)0 (0%)
Tumor stage      
 Stage I210 (55.1%)198 (49.6%)67 (47.9%)88 (18.7%)35 (14.6%)129 (17.6%)
 Stage II87 (22.8%)129 (32.3%)36 (25.7%)176 (37.4%)68 (28.3%)404 (55.0%)
 Stage III64 (16.8%)66 (16.6%)34 (24.3%)138 (29.4%)112 (46.7%)179 (24.4%)
 Stage IV20 (5.3%)6 (1.5%)3 (2.1%)68 (14.5%)25 (10.4%)22 (3.0%)
Follow-up time (days)609 (0-7248)671 (0-4765)662 (0-3478)648 (0-4502)415 (0-3720)838 (0-8605)
  1. Continuous variables are described with median and range. Categorical variables are described with counts and the percentages of each category
  2. Lung1 LUAD (lung adenocarcinoma), Lung2 LUSC (lung squamous cell carcinoma), Liver LIHC (liver hepatocellular carcinoma), Colorectal COAD + READ (colon adenocarcinoma), Stomach STAD (Stomach adenocarcinoma), Breast BRCA (breast invasive carcinoma)